MBRX

MBRX

USD

Moleculin Biotech Inc. Common Stock

$0.497+0.014 (2.836%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$0.483

高値

$0.502

安値

$0.470

出来高

2.28M

企業ファンダメンタルズ

時価総額

24.6M

業種

バイオテクノロジー

United States

取引統計

平均出来高

4.00M

取引所

NCM

通貨

USD

52週レンジ

安値 $0.25現在値 $0.497高値 $3.65

関連ニュース

GlobeNewswire

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting

HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat

もっと見る
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting
GlobeNewswire

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat

もっと見る
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
GlobeNewswire

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic cancer HOUSTON,

もっと見る
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
PR Newswire

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Equity InsiderNews Commentary – Conventional small molecule approaches have struggled to address genetic defects and complex disease mechanisms,...

もっと見る
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions